

# Contents

## Part I Clinical Aspects

<b>1 History of the Israeli Cohort of Laron Syndrome Patients (1958–2009)</b> .....	3
Zvi Laron	
<b>2 Early Investigations: Characterizations of the Circulating Growth Hormone</b> .....	9
Zvi Laron	
<b>3 Clinical Evidence of Growth Hormone Resistance in Patients with Laron Syndrome.</b> .....	21
Zvi Laron	
<b>4 Diagnosis of Laron Syndrome.</b> .....	27
Zvi Laron	
<b>5 Genetic Aspects</b> .....	29
Orit Shevah and Zvi Laron	
<b>5.1 Genetic Investigations.</b> .....	29
Orit Shevah and Zvi Laron	
<b>5.2 Hypothesis of the Origin of Laron Syndrome</b> .....	47
Zvi Laron and Orit Shevah	
<b>5.3 Are the Pygmies Laron Syndrome Patients?</b> .....	50
Zvi Laron	
<b>6 Clinical Evaluation.</b> .....	53
Zvi Laron	
<b>7 Perinatal Development in Laron Syndrome</b> .....	59
Zvi Laron and Rivka Kauli	
<b>8 Linear Growth Pattern of Untreated Laron Syndrome Patients</b> .....	63
Zvi Laron and Rivka Kauli	

<b>9 Head Shape, Size, and Growth of Untreated Patients with Laron Syndrome</b> . . . . .	91
Zvi Laron and Rivka Kauli	
<b>10 Sexual Development in Patients with Laron Syndrome</b> . . . . .	101
Zvi Laron and Rivka Kauli	
<b>11 Sex Hormone Binding Proteins and Sex Hormones in Untreated and IGF-I Treated Patients with Laron Syndrome</b> . . . . .	119
Zvi Laron and Rivka Kauli	
<b>11.1 Sex Hormone Binding Proteins</b> . . . . .	119
Zvi Laron	
<b>11.2 Sex Hormones in Untreated Patients with Laron Syndrome</b> . . . . .	121
Zvi Laron and Rivka Kauli	
<b>12 The Adipose Tissue in Patients with Laron Syndrome</b> . . . . .	125
Zvi Laron	
<b>13 Investigations to Determine the Cause of Obesity in Patients with Laron Syndrome</b> . . . . .	135
Zvi Laron, Shira Ginsberg, and Nahum Vaisman	
<b>14 Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Laron Syndrome</b> . . . . .	143
Zvi Laron	
<b>15 Serum Lipids in Patients with Laron Syndrome</b> . . . . .	149
Zvi Laron	
<b>16 Adiponectin and Leptin in Laron Syndrome</b> . . . . .	157
Zvi Laron and Hannah Kanety	
<b>17 Muscle Force and Endurance in Untreated Adult and IGF-I Treated Children with Laron Syndrome</b> . . . . .	161
Zvi Laron	
<b>18 Bone Mineral Density in Untreated and IGF-I or Alendronate-Treated Patients with Laron Syndrome</b> . . . . .	165
Zvi Laron	
<b>19 Muscle–Bone Relationship in Patients with Laron Syndrome</b> . . . . .	171
Yoram Epstein, Amir Hadid, Zvi Laron, Daniel S. Moran, and Nahum Vaisman	
<b>19.1 Bone Characteristics</b> . . . . .	171
Yoram Epstein, Amir Hadid, Zvi Laron, and Daniel S. Moran	
<b>19.2 Lean Body Mass (LBM) in Patients with Laron Syndrome</b> . . . . .	173
Zvi Laron and Nahum Vaisman	

<b>20 Imaging Findings in Laron Syndrome . . . . .</b>	<b>175</b>
Liora Kornreich and Zvi Laron	
<b>21 Ocular Findings in Laron Syndrome . . . . .</b>	<b>201</b>
Dan H. Bourla and Dov Weinberger	
<b>22 Hearing in Patients with Laron Syndrome . . . . .</b>	<b>209</b>
Zvi Laron, Omer Zarchi, and Joseph Attias	
<b>23 The Teeth in Patients with Laron Syndrome . . . . .</b>	<b>213</b>
Zvi Laron	
<b>24 Hair, Skin, and Nails in Patients with Laron Syndrome . . . . .</b>	<b>219</b>
Zvi Laron	
<b>25 Hand, Foot, and Organ Size and Growth in Untreated and IGF-I Treated Patients with Laron Syndrome . . . . .</b>	<b>227</b>
Zvi Laron and Aviva Silbergeld	
<b>25.1 Hand Size and Growth of Untreated and IGF-I Treated Laron Syndrome Patients . . . . .</b>	<b>227</b>
Zvi Laron	
<b>25.2 Foot Size and Growth in Untreated and IGF-I-Treated Patients with Laron Syndrome . . . . .</b>	<b>231</b>
Zvi Laron and Aviva Silbergeld	
<b>25.3 Organ Size . . . . .</b>	<b>233</b>
Zvi Laron	
<b>26 Lifelong Serum Growth Hormone Levels in Patients with Laron Syndrome . . . . .</b>	<b>235</b>
Zvi Laron and Orly Efros	
<b>27 IGF-I Binding Proteins in Laron Syndrome . . . . .</b>	<b>241</b>
Zvi Laron	
<b>28 Serum Prolactin in Untreated and IGF-I Treated Patients with Laron Syndrome . . . . .</b>	<b>247</b>
Zvi Laron and Orly Efros	
<b>29 Thyroid Hormones in Untreated and IGF-I Treated Patients with Laron Syndrome . . . . .</b>	<b>255</b>
Zvi Laron and Rivka Kauli	
<b>30 Insulin Secretion and Carbohydrate Metabolism in Patients with Laron Syndrome: From Hypoglycemia to Diabetes Mellitus . . . . .</b>	<b>259</b>
Zvi Laron	
<b>31 Liver Enzymes in Patients with Laron Syndrome . . . . .</b>	<b>273</b>
Zvi Laron and Tsvia Karmon	

<b>32 The Hematopoietic System in Patients with Laron Syndrome . . . . .</b>	<b>283</b>
Zvi Laron	
<b>33 Cardiovascular Aspects in Laron Syndrome Patients . . . . .</b>	<b>293</b>
Mickey Scheinowitz, Micha S. Feinberg, Michael Shechter, Zvi Laron, and Rivka Kauli	
<b>33.1 Heart Functions in Untreated and IGF-I-Treated Patients with Laron Syndrome . . . . .</b>	<b>293</b>
Mickey Scheinowitz, Micha S. Feinberg, and Zvi Laron	
<b>33.2 Endothelial Function in Adults with Laron Syndrome (Primary Growth Hormone Insensitivity) . . . . .</b>	<b>298</b>
Michael Shechter and Zvi Laron	
<b>33.3 Intimal Thickness of the Extracranial Arteries in Untreated Adult Patients with Laron Syndrome . . . . .</b>	<b>300</b>
Zvi Laron	
<b>33.4 Cardiovascular Disease. . . . .</b>	<b>303</b>
Zvi Laron and Rivka Kauli	
<b>34 Kidney Functions in Untreated and IGF-I Treated Patients with Laron Syndrome . . . . .</b>	<b>307</b>
Zvi Laron	
<b>35 Sleep and Sleep Disorders in Patients with Laron Syndrome . . . . .</b>	<b>317</b>
Zvi Laron, Rivka Kauli, and Eyal Rosenzweig	
<b>35.1 Sleep Quality . . . . .</b>	<b>317</b>
Zvi Laron and Rivka Kauli	
<b>35.2 Severe Obstructive Sleep Apnea (OSA) . . . . .</b>	<b>318</b>
Zvi Laron	
<b>35.3 Additional Polysomnographic Examinations of Patients with Laron Syndrome . . . . .</b>	<b>318</b>
Eyal Rosenzweig and Zvi Laron	
<b>36 Neurological Aspects in Laron Syndrome . . . . .</b>	<b>321</b>
Zvi Laron	
<b>37 Orthopedic Problems in Laron Syndrome . . . . .</b>	<b>323</b>
Zvi Laron and Rivka Kauli	
<b>38 Psychological Aspects in Patients with Laron Syndrome. . . . .</b>	<b>325</b>
Zvi Laron	
<b>39 Adjustment and Rehabilitation Problems of Children, Adolescents, and Adults with Laron Syndrome. . . . .</b>	<b>335</b>
Zvi Laron	
<b>40 Laron Syndrome Patients with Congenital IGF-I Deficiency Seem Protected from Malignant Diseases . . . . .</b>	<b>339</b>
Zvi Laron, Rachel Steuerman, and Orit Shevah	

<b>41 Lifespan and Mortality of Patients with Laron Syndrome . . . . .</b>	<b>341</b>
Zvi Laron	
<b>42 IGF-I Treatment of Patients with Laron Syndrome . . . . .</b>	<b>343</b>
Zvi Laron	
<b>43 IGF-I Stimulation of Head Growth in Patients with Laron Syndrome . . . . .</b>	<b>381</b>
Zvi Laron	
<b>44 Effects of Long-Term Administration of IGF-I on the Adipose Tissue and Carbohydrate Metabolism in Children with Laron Syndrome . . . . .</b>	<b>389</b>
Zvi Laron	
<b>45 Comparison of the Growth Promoting Response of IGF-I in Children with Laron Syndrome with that of hGH in Children with Isolated GH Deficiency . . . . .</b>	<b>409</b>
Zvi Laron	
<b>46 IGF-I Treatment of Adult Patients with Laron Syndrome . . . . .</b>	<b>413</b>
Zvi Laron	
<b>47 Adverse Effects Encountered During IGF-I Treatment of Patients with Laron Syndrome . . . . .</b>	<b>419</b>
Zvi Laron	
<b>48 Summary of the Clinical History: The Laron Syndrome Clock . . . . .</b>	<b>425</b>
Zvi Laron	
 <b>Part II The Growth Hormone Receptor “Null” Mouse or the Laron Mouse</b>	
<b>49 The Laron Mouse . . . . .</b>	<b>429</b>
John J. Kopchick and John D. Blischak	
<b>50 Role of GH/IGF-I Deficiency in Aging . . . . .</b>	<b>433</b>
Edward O. List	
<b>51 Body Composition, Adipose Tissue, and Energy Balance . . . . .</b>	<b>441</b>
Darlene E. Berryman	
<b>52 Metabolism and Metabolic Regulation . . . . .</b>	<b>451</b>
Lucila Sackmann-Sala, D. R. Bailey Miles, and John J. Kopchick	
<b>53 Skeletal Muscle . . . . .</b>	<b>465</b>
Juan Ding and John J. Kopchick	

---

<b>54 Cardiac Function in GHR<sup>-/-</sup> Mice</b> .....	473
Diana Cruz-Topete and John J. Kopchick	
<b>55 Bone</b> .....	481
Shigeru Okada and Jacob Wright-Piekarski	
<b>56 GHR Knockout and the CNS</b> .....	489
Elahu S. Gosney and John J. Kopchick	
<b>57 Cancer</b> .....	495
Brian D. Bower and John J. Kopchick	
<b>58 Reproduction</b> .....	507
Bruce Kelder	
<b>59 Conclusions and Future Studies</b> .....	513
John J. Kopchick, Hiroyoshi Tanda, Darlene Berryman, and Zvi Laron	
<b>Appendix</b> .....	521
<b>Index</b> .....	525

Laron Syndrome - From Man to Mouse

Lessons from Clinical and Experimental Experience

Laron, Z.; Kopchick, J. (Eds.)

2011, XIV, 531 p., Hardcover

ISBN: 978-3-642-11182-2